Can Shield Bring More People into Colorectal Cancer Screening? ↗
Compares screening follow-up with postoperative treatment selection, not test performance.
Commercialization · TOPIC v1
Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
How can molecular evidence of residual cancer guide postoperative treatment?
Read article → Signatera: Using Tumor DNA in Blood to Guide Treatment After Surgery
2026-09-29 15:11:40.000 UTC · Last recorded update
CURRENT READING
Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
Recorded editorial state, not a maturity score
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened · v1
Recorded a new question and follow-up checks from the approved manuscript.
Permanent link to this revision ↗01 / WHAT WE TRACK
How can molecular evidence of residual cancer guide postoperative treatment?
02 / EVIDENCE & TECHNOLOGY
Tumor-informed ctDNA / MRD
03 / EDITORIAL READING
Screening and postoperative treatment selection lead to different decisions after a blood test.
04 / WHAT REMAINS UNKNOWN
The setting is postoperative muscle-invasive bladder cancer; do not generalize to test-negative patients or other cancers.
05 / NEXT CHECK
Track the authorized population and treatment conditions.
A hypothesis to keep honest
HYPOTHESIS · NOT YET TESTEDEvidence linking a test to treatment may make postoperative treatment decisions more specific.
What would change our view: Reassess the expected benefit when trial or patient conditions differ.
A prospective test proposal, not a prediction score. A graph connection does not validate this hypothesis.
Linked people & organizations
Open an entity to find its cardsINSTITUTION / INFRASTRUCTURENatera ↗
Mentioned in this issue
Related questions, optional follows
Map ↗Therapy & companion diagnostics ↗
Adds a distinct product and indication to the question of linking tests with therapy.
Changing treatment before scans show progression: a new relationship between breast cancer drugs and blood tests ↗
Compares postoperative treatment selection with timing a switch during treatment, across different cancers and products rather than comparing test performance.
From testing a patient's cancer to making their treatment ↗
Compare MRD-guided treatment selection with patient-specific antigen design, without equating efficacy or indications.
Latest card updates
Latest 5 · editorial record dates- v1 · 2026-09-29 15:11:40.000 UTCNew question opened
Recorded a new question and follow-up checks from the approved manuscript.
Reading at the time: Natera announced Japanese companion-diagnostic approval; additional treatment in test-positive patients has been assessed in a comparative trial.
Earlier updates (0)
Earlier entries will appear here once more than five reader-facing revisions have accumulated.
Background readings
Source dates and verification scope
企業発表 ↗
www.natera.com · recorded 2026-09-29 · linked-primary-source
FDAの検査情報 ↗
www.accessdata.fda.gov · recorded 2026-09-29 · linked-primary-source
臨床試験 ↗
pubmed.ncbi.nlm.nih.gov · recorded 2026-09-29 · linked-primary-source